Sign in
Stories
T2 Biosystems Wins Lyme Diagnostics Prize
Share
Diagnostic Market Evolution Amid Advance...
Eradicating TB: Optimism and Challenges,...
Global Tuberculosis Initiatives
Advancing OSE-279: Promising Cancer Trea...
Asia Pacific Poised for Diagnostics Grow...
Beckman Coulter Unveils DxC 500 AU Chemi...
Overview
API
T2 Biosystems, Inc. has been selected as a Phase 2 winner in the LymeX Diagnostics Prize, receiving $265,000 from the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation. The company's T2Lyme™ Panel is a direct-from-blood molecular diagnostic test for detecting Borrelia burgdorferi, the bacteria causing Lyme disease. T2 Biosystems is committed to improving patient care through rapid detection of pathogens and antibiotic resistance genes.
Ask a question
How could the success of T2 Biosystems in the Lyme diagnostics prize influence the broader healthcare industry?
How might the T2Lyme™ Panel impact the diagnosis and treatment of Lyme disease?
What are the potential implications of the rapid detection of sepsis-causing pathogens and antibiotic resistance genes?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage